WO2004098515A3 - Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer - Google Patents

Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer Download PDF

Info

Publication number
WO2004098515A3
WO2004098515A3 PCT/US2004/013568 US2004013568W WO2004098515A3 WO 2004098515 A3 WO2004098515 A3 WO 2004098515A3 US 2004013568 W US2004013568 W US 2004013568W WO 2004098515 A3 WO2004098515 A3 WO 2004098515A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
useful
detection
treatment
nucleic acids
Prior art date
Application number
PCT/US2004/013568
Other languages
French (fr)
Other versions
WO2004098515A2 (en
Inventor
Arthur B Raitano
Pia M Challita-Eid
Wangmao Ge
Juan J Perez-Villar
Steven B Kanner
Aya Jakobovits
Original Assignee
Agensys Inc
Arthur B Raitano
Pia M Challita-Eid
Wangmao Ge
Juan J Perez-Villar
Steven B Kanner
Aya Jakobovits
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc, Arthur B Raitano, Pia M Challita-Eid, Wangmao Ge, Juan J Perez-Villar, Steven B Kanner, Aya Jakobovits filed Critical Agensys Inc
Priority to CA2522994A priority Critical patent/CA2522994C/en
Priority to JP2006514206A priority patent/JP2007525183A/en
Priority to AU2004235755A priority patent/AU2004235755A1/en
Priority to EP04760669A priority patent/EP1622571A4/en
Publication of WO2004098515A2 publication Critical patent/WO2004098515A2/en
Priority to AU2008212020A priority patent/AU2008212020B2/en
Publication of WO2004098515A3 publication Critical patent/WO2004098515A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A novel gene 109P1D4 and its encoded protein, and variants thereof, are described wherein 109P1D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table i. Consequently, 109P1D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 109P1D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 109P1D4 can be used in active or passive immunization.
PCT/US2004/013568 2003-04-30 2004-04-30 Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer WO2004098515A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2522994A CA2522994C (en) 2003-04-30 2004-04-30 Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
JP2006514206A JP2007525183A (en) 2003-04-30 2004-04-30 Nucleic acids and corresponding proteins called 109P1D4 useful in the treatment and detection of cancer
AU2004235755A AU2004235755A1 (en) 2003-04-30 2004-04-30 Nucleic acids and corresponding proteins entitled 109P1D4 useful in treatment and detection of cancer
EP04760669A EP1622571A4 (en) 2003-04-30 2004-04-30 Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
AU2008212020A AU2008212020B2 (en) 2003-04-30 2008-09-05 Nucleic acids and corresponding proteins entitled 109P1D4 useful in treatment and detection of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46700203P 2003-04-30 2003-04-30
US60/467,002 2003-04-30

Publications (2)

Publication Number Publication Date
WO2004098515A2 WO2004098515A2 (en) 2004-11-18
WO2004098515A3 true WO2004098515A3 (en) 2009-04-30

Family

ID=33435005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013568 WO2004098515A2 (en) 2003-04-30 2004-04-30 Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer

Country Status (5)

Country Link
EP (1) EP1622571A4 (en)
JP (2) JP2007525183A (en)
AU (2) AU2004235755A1 (en)
CA (1) CA2522994C (en)
WO (1) WO2004098515A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
WO2006086345A2 (en) * 2005-02-07 2006-08-17 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity
CA2647728C (en) * 2006-03-31 2014-12-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 gene
JP6236948B2 (en) * 2013-07-17 2017-11-29 東ソー株式会社 Antibody eluate and antibody purification method using the eluate
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
AU2016221305B2 (en) 2015-02-18 2021-05-27 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
JP6884155B2 (en) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド Combination immunotherapy and cytokine control therapy for cancer treatment
TWI795381B (en) * 2016-12-21 2023-03-11 比利時商健生藥品公司 Pyrazole derivatives as malt1 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057190A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443123A1 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057190A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1622571A4 *

Also Published As

Publication number Publication date
JP2007525183A (en) 2007-09-06
AU2004235755A1 (en) 2004-11-18
AU2008212020B2 (en) 2012-05-24
EP1622571A4 (en) 2012-05-02
CA2522994C (en) 2012-09-25
EP1622571A2 (en) 2006-02-08
CA2522994A1 (en) 2004-11-18
AU2008212020A1 (en) 2008-09-25
WO2004098515A2 (en) 2004-11-18
JP2011152132A (en) 2011-08-11

Similar Documents

Publication Publication Date Title
WO2004016734A3 (en) Nucleic acids and corresponding proteins entitled 282p1g3 useful in treatment and detection of cancer
WO2003022995A3 (en) Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
WO2003040340A3 (en) Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
EP2280030A3 (en) Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
IL181218A0 (en) Nucleic acids and corresponding 58p1d12 proteins for use in the detection and treatment of cancer
WO2005014780A3 (en) Prostate stem cell antigen (psca) variants and subsequences thereof
WO2005118864A3 (en) Antibodies and related molecules that bind to psca proteins
WO2006105488A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
WO2004098515A3 (en) Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
CY1113064T1 (en) NUCLEAR ACID AND CORRESPONDING PROTEIN WITH TITLE 184P1E2 USEFUL IN CANCER TREATMENT AND DETECTION
WO2003050255A3 (en) Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
WO2004067716A3 (en) Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
WO2002072785A3 (en) Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer
WO2002060953A3 (en) Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
WO2006055004A8 (en) Nucleic acids and corresponding proteins entitled 158p3d2 useful in treatment and detection of cancer
WO2002083928A3 (en) Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
WO2002092842A3 (en) Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer
WO2004050828A3 (en) Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer
WO2002095009A3 (en) Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer
WO2004021977A3 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
WO2003085081A3 (en) Nucleic acid and corresponding protein entitled 238p1b2 useful in treatment and detection of cancer
WO2002083068A8 (en) Nucleic acid and corresponding protein entitled 121p2a3 useful in treatment and detection of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 171505

Country of ref document: IL

Ref document number: 2522994

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006514206

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2004760669

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004235755

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004235755

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004760669

Country of ref document: EP